ArticleFrontiers in cardiovascular medicine2026
Percutaneous extracorporeal ventricular assist device as a successful bridge strategy to durable left ventricular assist device in refractory cardiogenic shock: a case report.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiogenic shock (CS) is a life-threatening condition with high mortality. Temporary mechanical circulatory support (tMCS) is important for stabilizing patients with refractory CS, acting as a bridge to recovery, decision-making for durable left ventricular assist device (LVAD) implantation or transplantation. In China, commonly used devices like intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO) have limitations such as inadequate ventricular unloading and high complication rates, and advanced options like Impella, TandemHeart and CentriMag are not widely available. This report presents a successful bridge to durable LVAD therapy case using a minimally invasive extracorporeal VAD in a high-risk CS patient. Case summary: A 39-year-old male with refractory cardiogenic shock due to ischemic cardiomyopathy is reported. He was not a candidate for immediate durable LVAD implantation or transplantation because of unstable hemodynamics, severe pulmonary edema, and active infection. Considering his condition, a percutaneous extracorporeal VAD was inserted through the right axillary artery and jugular vein, creating a bypass from the left atrium → across the atrial septum → right atrium → superior vena cava → right jugular vein → centrifugal pump → axillary artery. The operation was carried out without any complications, and the patient quickly improved. After 215 h and 43 min of support, he successfully received durable LVAD implantation. Discussion: This case demonstrates the clinical value of a minimally invasive extracorporeal VAD as a bridge-to-bridge therapy for critical cardiogenic shock. The percutaneous approach effectively unloads the left ventricle while minimizing complications. It promotes early patient mobilization, simplifies postoperative care, and lowers treatment costs. This method is technically simple and controllable in most hospital environments, offering practical guidance for managing high-risk shock patients, especially in places where advanced surgical options are restricted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.